Sanofi highlights robust performance in Q1 2017 results

Sanofi has announced its financial results for the first quarter of 2017, during which it delivered a net sales total of 8.65 billion euros (7.31 billion pounds).

This represents a year-on-year increase of 11 percent on a reported basis, or an 8.6 percent rise at constant exchange rates. This reflects the impact of the firm's recent acquisition of Boehringer Ingelheim's consumer healthcare business and the full consolidation of its European vaccine operations.

Sanofi's Genzyme business experienced double-digit growth, driven by strong demand for its multiple sclerosis therapies, while Sanofi Pasteur achieved success with its paediatric combinations. This helped to offset a decline in diabetes and cardiovascular sales.

Key highlights of the quarter include the launch of the atopic dermatitis therapy Dupixent in the US, as well the conclusion of Sanofi Pasteur joint venture with Merck Sharp and Dohme, meaning Sanofi is now in full control of the vaccines business.

Olivier Brandicourt, chief executive officer of Sanofi, said: "We have started the year with robust growth, driven by specialty care and vaccines, as well as good performance in emerging markets."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.